Abeona Therapeutics Inc.

NASDAQ:ABEO

6.25 (USD) • At close November 1, 2024
Bedrijfsnaam Abeona Therapeutics Inc.
Symbool ABEO
Munteenheid USD
Prijs 6.25
Beurswaarde 270,715,000
Dividendpercentage 0%
52-weken bereik 3.05 - 9.01
Industrie Biotechnology
Sector Healthcare
CEO Dr. Vishwas Seshadri M.B.A., Ph.D.
Website https://www.abeonatherapeutics.com

An error occurred while fetching data.

Over Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy

Vergelijkbare Aandelen

Ekso Bionics Holdings, Inc. logo

Ekso Bionics Holdings, Inc.

EKSO

0.887 USD

Onconova Therapeutics, Inc. logo

Onconova Therapeutics, Inc.

ONTX

0.995 USD

Landos Biopharma, Inc. logo

Landos Biopharma, Inc.

LABP

22.93 USD

Sio Gene Therapies Inc. logo

Sio Gene Therapies Inc.

SIOX

0.415 USD

Aytu BioPharma, Inc. logo

Aytu BioPharma, Inc.

AYTU

1.938 USD

Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc.

CLRB

2.03 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)